progressive supranuclear palsy
Conditions
Interventions
Gold Standard:clinical diagnosis of progressive supranuclear palsy the movement disorder society criteria in 2017.(Mov Disord. 2017 Jun
32(6):853-864. doi: 10.1002/mds.26987. Epub 2017 May 3.).
value 
of 
Sponsors
Huashan Hospital, Fudan University
Eligibility
Sex/Gender
All
Age
45 Years to 80 Years
Inclusion criteria
Inclusion criteria: PSP patients: 1. Aged between 45 and 80 years; Gender is not limited. 2. The patient meets the diagnostic criteria for PSP (nnds-spsp 2017). 3. Brain MRI supports the diagnosis of PSP and there is no evidence of other neurological diseases. 4. Drugs used to improve the clinical symptoms of PSP should be maintained at a stable dose for more than 30 days before starting this study. 5. informed consent to be signed in person by the subject or his/her legal guardian/caretaker. 6. Subject may be accompanied by a nurse if necessary. 7. Subject or its legal representative understands and signs a written informed consent prior to any evaluation. 8. The female subject shall have a medical record to prove that she has undergone surgical sterilization (such as hysterectomy, bilateral ovariectomy or tubal ligation) or has gone through menopause for more than one year; If you still have the ability to conceive, you should use isolated contraception at this stage of the study. 9. Male subjects are required to use isolated contraception at this stage of the study. Male subjects are not allowed to donate sperm during the study period. 10. Willing and able to cooperate with all projects of this study. Control: 1. Aged between 45 and 80 years; Gender is not limited. 2. Normal motor and cognitive functions were recognized by researchers through cognitive tests. CDR score was 0; The UPDRS score is 0. 3. No neurological diseases, major chronic diseases, malignant tumors or acute infectious diseases were identified by the researchers. 4. No family history of PSP, no family history of neurological diseases related to cognitive impairment or movement disorder. 5. understanding and signing of written informed consent prior to any assessment. 6. The female subject shall have a medical record to prove that she has undergone surgical sterilization (such as hysterectomy, bilateral ovariectomy or tubal ligation) or menopause for more than one year; If you still have the ability to conceive, you should use isolated contraception at this stage of the study. 7. Male subjects are required to use isolated contraception at this stage of the study. Male subjects are not allowed to donate sperm during the study period. 8. Willingness and ability to cooperate with all projects of this study.
Exclusion criteria
Exclusion criteria: 1. All subjects: i. suffered from serious other neurological diseases, or gastrointestinal, cardiovascular, liver, kidney, hematological system, tumor, endocrine, respiratory system, immune deficiency and other serious diseases. 2. Implanted metal devices that are not compatible with MRI, including cardiac pacemakers, intravascular metal devices, insulin pumps, cochlear implants, nerve stimulators, and brain aneurysm clips. 3. Inability to tolerate MRI noise or hermetic phobia. 4. In the past year, ionizing radiation outside the scope of this trial was received due to other clinical or scientific research needs, resulting in an annual radiation exposure dose exceeding 50 mSv. 5. History of drug or alcohol abuse. 6. Pregnant or nursing women. 7. Poor venous conditions, unable to tolerate repeated venipuncture. 8. Received an experimental drug or device treatment (with unclear efficacy or safety) within 1 month. Poor venous condition, unable to tolerate repeated venipuncture. 9. May be allergic to the component of [18F]-APN-1607([18F]PM-PBB3) injection. 10. There are any conditions in which the leader of the study considers any part of the trial to be hazardous or potentially hazardous. II. PSP patients received tau drug therapy within 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Standard uptake value ratio; | — |
Countries
China
Contacts
Public ContactYihui Guan
PET Center, Huashan Hospital, Fudan University
Outcome results
None listed